- Home
- ABOS vs EDF Comparison
ABOS vs EDF Comparison
Compare ABOS & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABOS | EDF |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.7M | 153.0M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ABOS | EDF |
|---|---|---|
| Price | $2.59 | $5.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 473.4K | 230.3K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $4.14 |
| 52 Week High | $3.60 | $5.34 |
Technical Indicators
Market Signals| Indicator | ABOS | EDF |
|---|---|---|
| Relative Strength Index (RSI) | 38.37 | 46.47 |
| Support Level | $1.21 | $4.95 |
| Resistance Level | $3.05 | $5.04 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 5.56 | 54.84 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.